-
Je něco špatně v tomto záznamu ?
The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01
U. Creutzig, M. Zimmermann, MN. Dworzak, B. Gibson, R. Tamminga, J. Abrahamsson, SY. Ha, H. Hasle, A. Maschan, Y. Bertrand, G. Leverger, C. von Neuhoff, B. Razzouk, C. Rizzari, P. Smisek, OP. Smith, B. Stark, D. Reinhardt, GL. Kaspers,
Jazyk angličtina Země Itálie
Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie
NLK
Directory of Open Access Journals
od 1994
Free Medical Journals
od 1994
Freely Accessible Science Journals
od 1994
PubMed Central
od 2009
Europe PubMed Central
od 2009
Open Access Digital Library
od 1994-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1996
- MeSH
- akutní myeloidní leukemie diagnóza farmakoterapie mortalita patologie MeSH
- analýza přežití MeSH
- buňky kostní dřeně účinky léků patologie MeSH
- daunomycin terapeutické užití MeSH
- dítě MeSH
- indukce remise MeSH
- lidé MeSH
- mladiství MeSH
- monitorování léčiv MeSH
- předškolní dítě MeSH
- prognóza MeSH
- protinádorová antibiotika terapeutické užití MeSH
- protokoly protinádorové kombinované chemoterapie MeSH
- recidiva MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
The prognostic significance of early response to treatment has not been reported in relapsed pediatric acute myeloid leukemia. In order to identify an early and easily applicable prognostic factor allowing subsequent treatment modifications, we assessed leukemic blast counts in the bone marrow by morphology on days 15 and 28 after first reinduction in 338 patients of the international Relapsed-AML2001/01 trial. Both day 15 and day 28 status was classified as good (≤20% leukemic blasts) in 77% of patients. The correlation between day 15 and 28 blast percentages was significant, but not strong (Spearman correlation coefficient = 0.49, P<0.001). Survival probability decreased in a stepwise fashion along with rising blast counts at day 28. Patients with bone marrow blast counts at this time-point of ≤5%, 6-10%, 11-20% and >20% had 4-year probabilities of survival of 52%±3% versus 36%±10% versus 21%±9% versus 14%±4%, respectively, P<0.0001; this trend was not seen for day 15 results. Multivariate analysis showed that early treatment response at day 28 had the strongest prognostic significance, superseding even time to relapse (< or ≥12 months). In conclusion, an early response to treatment, measured on day 28, is a strong and independent prognostic factor potentially useful for treatment stratification in pediatric relapsed acute myeloid leukemia. This study was registered with ISRCTN code: 94206677.
AIEOP c o Department of Pediatrics Hospital S Gerardo Monza Italy
BFM AML Group Hannover c o Pediatric Hematology Oncology Hannover Medical High School Germany
c o Department of Haematology and Oncology Our Lady's Children's Hospital Dublin Ireland
c o Unité d'Onco Hématologie Pédiatrique Hôpital d'Enfants Armand Trousseau Paris France
Department of Pediatrics Aarhus University Hospital Skejby Denmark
FRALLE CLCG c o Institut d'Hématologie et d'Oncologie Pédiatrique Lyon France
NOPHO Department of Pediatrics Queen Silvia's Children's Hospital Göteborg Sweden
Research Center for Pediatric Hematology Oncology and Immunology Moscow Russia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15023459
- 003
- CZ-PrNML
- 005
- 20150729122510.0
- 007
- ta
- 008
- 150709s2014 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3324/haematol.2014.104182 $2 doi
- 035 __
- $a (PubMed)24763401
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Creutzig, Ursula $u BFM-AML Group, Hannover, c/o Pediatric Hematology/Oncology, Hannover Medical High School, Germany ursula@creutzig.de.
- 245 14
- $a The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01 / $c U. Creutzig, M. Zimmermann, MN. Dworzak, B. Gibson, R. Tamminga, J. Abrahamsson, SY. Ha, H. Hasle, A. Maschan, Y. Bertrand, G. Leverger, C. von Neuhoff, B. Razzouk, C. Rizzari, P. Smisek, OP. Smith, B. Stark, D. Reinhardt, GL. Kaspers,
- 520 9_
- $a The prognostic significance of early response to treatment has not been reported in relapsed pediatric acute myeloid leukemia. In order to identify an early and easily applicable prognostic factor allowing subsequent treatment modifications, we assessed leukemic blast counts in the bone marrow by morphology on days 15 and 28 after first reinduction in 338 patients of the international Relapsed-AML2001/01 trial. Both day 15 and day 28 status was classified as good (≤20% leukemic blasts) in 77% of patients. The correlation between day 15 and 28 blast percentages was significant, but not strong (Spearman correlation coefficient = 0.49, P<0.001). Survival probability decreased in a stepwise fashion along with rising blast counts at day 28. Patients with bone marrow blast counts at this time-point of ≤5%, 6-10%, 11-20% and >20% had 4-year probabilities of survival of 52%±3% versus 36%±10% versus 21%±9% versus 14%±4%, respectively, P<0.0001; this trend was not seen for day 15 results. Multivariate analysis showed that early treatment response at day 28 had the strongest prognostic significance, superseding even time to relapse (< or ≥12 months). In conclusion, an early response to treatment, measured on day 28, is a strong and independent prognostic factor potentially useful for treatment stratification in pediatric relapsed acute myeloid leukemia. This study was registered with ISRCTN code: 94206677.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a protinádorová antibiotika $x terapeutické užití $7 D000903
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $7 D000971
- 650 _2
- $a buňky kostní dřeně $x účinky léků $x patologie $7 D001854
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a daunomycin $x terapeutické užití $7 D003630
- 650 _2
- $a monitorování léčiv $7 D016903
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a akutní myeloidní leukemie $x diagnóza $x farmakoterapie $x mortalita $x patologie $7 D015470
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a analýza přežití $7 D016019
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Zimmermann, Martin $u BFM-AML Group, Hannover, c/o Pediatric Hematology/Oncology, Hannover Medical High School, Germany.
- 700 1_
- $a Dworzak, Michael N $u BFM-AML Group, St. Anna Children's Hospital and Children's Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, Austria.
- 700 1_
- $a Gibson, Brenda $u UK NCRI Childhood Leukaemia Group, Department of Paediatric Haematology, Royal Hospital for Sick Children, Glasgow, Scotland, UK.
- 700 1_
- $a Tamminga, Rienk $u Pediatric Oncology/Hematology, Beatrix Children's Hospital/UMCG, Groningen, The Netherlands Dutch Childhood Oncology Group, The Hague, The Netherlands.
- 700 1_
- $a Abrahamsson, Jonas $u NOPHO, Department of Pediatrics, Queen Silvia's Children's Hospital, Göteborg, Sweden. $7 gn_A_00000748
- 700 1_
- $a Ha, Shau-Yin $u Hong Kong Paediatric Haematology & Oncology Study Group, c/o Department of Paediatrics & Adolescent Medicine, Queen Mary Hospital, Hong Kong, China.
- 700 1_
- $a Hasle, Henrik $u NOPHO; Department of Pediatrics, Aarhus University Hospital Skejby, Denmark.
- 700 1_
- $a Maschan, Alexey $u Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
- 700 1_
- $a Bertrand, Yves $u FRALLE/CLCG, c/o Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France.
- 700 1_
- $a Leverger, Guy $u FRALLE/CLCG; c/o Unité d'Onco-Hématologie Pédiatrique, Hôpital d'Enfants Armand Trousseau, Paris, France.
- 700 1_
- $a von Neuhoff, Christine $u BFM-AML Group, Hannover, c/o Pediatric Hematology/Oncology, Hannover Medical High School, Germany.
- 700 1_
- $a Razzouk, Bassem $u St. Jude's Children Research Hospital, Memphis, TN, USA, c/o Children's Center For Cancer and Blood Diseases, Peyton Manning Children's Hospital at St. Vincent, Indianapolis, IN, USA.
- 700 1_
- $a Rizzari, Carmelo $u AIEOP, c/o Department of Pediatrics, Hospital S. Gerardo, Monza, Italy.
- 700 1_
- $a Smisek, Petr $u CPH, c/o Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine and University Hospital Motol, Charles University Prague, Czech Republic.
- 700 1_
- $a Smith, Owen P $u UK CCLG; c/o Department of Haematology & Oncology, Our Lady's Children's Hospital, Dublin, Ireland.
- 700 1_
- $a Stark, Batia $u Center of Pediatric Hematology/Oncology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
- 700 1_
- $a Reinhardt, Dirk $u BFM-AML Group, Hannover, c/o Pediatric Hematology/Oncology, Hannover Medical High School, Germany.
- 700 1_
- $a Kaspers, Gertjan L $u Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands Dutch Childhood Oncology Group, The Hague, The Netherlands.
- 773 0_
- $w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 99, č. 9 (2014), s. 1472-8
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24763401 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150709 $b ABA008
- 991 __
- $a 20150729122556 $b ABA008
- 999 __
- $a ok $b bmc $g 1083796 $s 906452
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 99 $c 9 $d 1472-8 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
- LZP __
- $a Pubmed-20150709
